Director David Moatazedi sold 127,905 shares (127.9K shares) for $1,283,195.27 in 2 transactions on 2025-06-13 and 2025-06-16
David Moatazedi sold 127.9K shares at a blended average price of $10.03 across two separate transactions, reducing his position by 26.0% from 492.8K to 364.9K shares. The stock is currently trading at $9.96, down 43.0% from its 52-week high of $17.49 and down 25.0% over the past 90 days, despite a recent 2.7% 30-day gain. His prior trades at EOLS show mixed timing: 2 of 5 prior sells were well-timed at the 90-day mark (stock declined after the sale), while 3 were poorly timed (stock rose). The company is unprofitable with a net loss of $18.9M in the latest quarter, though it posted 31.8% annual revenue growth, leaving unclear whether this sale reflects a strategic reassessment or portfolio rebalancing given the incomplete profitability picture.
Evolus director Moatazedi sold 103.4K shares at $13.26 (−24.2% from high); stock down −10.4% in 30 days post-sale.
MOATAZEDI DAVID sold 103,376 shares of Evolus on 2025-03-18 at $13.26, reducing his holdings from 618,246 to 514,870 shares, a −16.7% reduction. The sale price is −24.2% from the 52-week high of $17.49, and the stock has fallen −10.4% in the 30 days since the transaction. Over his same-ticker history at EOLS (4 prior sales), 1 of 4 prior sells achieved negative 90-day returns, and the most recent transaction on 2024-03-19 resulted in a −21.9% 90-day decline. The company posted a net loss of $-19.2M against $61.1M quarterly revenue, indicating ongoing unprofitability despite +31.8% annual revenue growth. The confluence of a large share reduction at a depressed valuation, immediate post-sale weakness, and the company's negative earnings profile creates a signal worth monitoring, though the individual sale alone does not provide definitive directional conviction without additional context on open position composition or planned activity.
